Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omnibus spending bill

This article was originally published in The Tan Sheet

Executive Summary

House, Senate agree to conference report on FY 2003 approps bill Feb. 13, providing $413.3 mil. for CFSAN, $426.7 mil. for CDER. Total FDA budget is $1.63 bil., including $222.9 mil. in PDUFA fees. Funding levels are similar to those in version passed by lower chamber (1"The Tan Sheet," Jan. 27, 2003, In Brief)...

You may also be interested in...



Omnibus appropriations signed

President Bush signs H.J. Res. 2 Feb. 20, providing federal government $397.4 bil. for FY 2003. House and Senate agreed to conference report Feb. 13 (1"The Tan Sheet" Feb. 17, 2003, In Brief)...

Omnibus bill clears Senate

Amendment that would allocate $10 mil. in FDA funding "for the continuance of methamphetamine reduction efforts" passes Senate by voice vote Jan. 23. Proposed by Sen. Charles Grassley (R-Iowa), amendment is one of more than 200 considered by upper chamber before it passed omnibus spending package (H J Res 2) the same day in a 69-29 vote. Measure would provide FDA with $1.63 bil. in FY 2003, of which $412.4 mil. would be allocated to CFSAN, $426.2 mil. to CDER. NCCAM would receive $114.1 mil., roughly $9 mil. above House-approved level. Next step is conference with lower chamber, which passed its omnibus package Jan. 8; Hill sources say conference process could be resolved by the Presidents' Day recess, although Congress faces "tremendous hurdles"...

Common Regulatory Starting Point Means EU-UK Are On Track For Medtech MRA, Say German Firms

With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel